ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 102,800 shares, a growth of 166.3% from the July 31st total of 38,600 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average trading volume of 20,300 shares, the days-to-cover ratio is presently 5.1 days.
A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating on shares of ESSA Pharma in a report on Friday, May 17th. ValuEngine lowered shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Zacks Investment Research upgraded shares of ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Wednesday, May 22nd.
Shares of NASDAQ EPIX traded down $0.17 during mid-day trading on Wednesday, hitting $2.77. 35,548 shares of the stock were exchanged, compared to its average volume of 16,424. The company has a market cap of $22.06 million, a P/E ratio of -1.09 and a beta of 1.85. The stock’s fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.63. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.06 and a current ratio of 1.06. ESSA Pharma has a twelve month low of $1.41 and a twelve month high of $4.50.
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Featured Article: What is dollar cost averaging (DCA)?
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.